

BACKGROUND

Management of atrial fibrillation (AF) remains challenging, with the gold standard being the Cox Maze procedure.

The Encompass (AtriCure, Inc, Cincinnati, OH) device allows a complete box lesion in a single application without left atriotomy.

We sought to assess the rate of sinus rhythm at short term follow-up and now present an update on previous data whereby a higher percentage of patients have made it to 1 year follow up.

METHODS

A retrospective review was performed with one hundred and fifty-five patients with a history of AF who underwent ablation during a concomitant cardiac surgical procedure with the AtriCure Encompass radiofrequency device between April 2022 and July 2024 at our institution. Patients were excluded if any additional device or lesion set was used.

Follow up was assessed at 1 month, 3 months, 6 months and 12 months.

CONCLUSION

For patients undergoing ‘closed heart’ surgery, we suggest concomitant radiofrequency ablation with the AtriCure Encompass device may offer enticing rates of maintenance of sinus rhythm at short term follow up.

RESULTS

Demographic / Comorbidities For All Comers and Cohorts with Sinus Rhythm at 1 Year Postoperatively			
	All Comers (n = 155)	Sinus Rhythm at 1 Year - YES (n = 44, 86%)	Sinus Rhythm at 1 Year - NO (n = 7, 14%)
Total Patients in Follow Up Period (n)	155 (100%)	51 (33%)	51 (33%)
Age	69.1 ± 8.9	68.6 ± 8.9	72.7 ± 6.0
Hispanic / Latino	8 (5%)	1 (2%)	0 (0%)
Race			
Caucasian	116 (75%)	33 (75%)	6 (86%)
African American	10 (7%)	3 (7%)	1 (14%)
Asian	18 (12%)	5 (11%)	0 (0%)
Native American	1 (1%)	1 (2%)	0 (0%)
Other	6 (4%)	3 (7%)	0 (0%)
Height (cm)	173.8 ± 10.0	175.0 ± 10.3	176.2 ± 9.3
Weight (kg)	90.7 ± 22.9	96.8 ± 28.9	90.44 ± 23.9
BMI	29.9 ± 6.4	31.4 ± 8.1	28.3 ± 5.6
STS Predicted Variables			
Mortality	2.4 ± 1.7	2.3 ± 1.8	2.8 ± 1.5
Stroke	1.5 ± 0.9	1.4 ± 1.0	1.8 ± 1.3
Morbidity / Mortality	15.5 ± 8.8	15.7 ± 10.2	21.8 ± 10.2
Diabetes	60 (39%)		
Dialysis Dependent	4 (3%)	0 (0%)	0 (0%)
Hypertension	130 (84%)	36 (82%)	5 (71%)

Demographic / Comorbidities For All Comers and Cohorts with Sinus Rhythm at 1 Year Postoperatively			
	All Comers (n = 155)	Sinus Rhythm at 1 Year - YES (n = 44, 86%)	Sinus Rhythm at 1 Year - NO (n = 7, 14%)
Cerebrovascular Disease	21 (14%)	4 (9%)	2 (29%)
Syncopal	4 (3%)	2 (5%)	1 (14%)
Beta Blockers	121 (78%)	38 (86%)	7 (100%)
Amiodarone			
Yes - home therapy	8 (5%)	3 (7%)	0 (0%)
Yes - started on admission	14 (9%)	5 (11%)	0 (0%)
None	133 (86%)	36 (82%)	7 (100%)
Ejection Fraction (%)	53 ± 12.5	54.1 ± 12.4*	43.6 ± 13.8*
Left Atrial Dimension (cm)	4.1 ± 0.9	3.9 ± 1.0	4.5 ± 0.6
Mitral Regurgitation			
Trivial / Trace	51 (33%)	12 (27%)	1 (14%)
Mild	62 (40%)	19 (43%)	5 (71%)
Moderate	23 (15%)	8 (18%)	0 (0%)
Severe	15 (10%)	3 (7%)	1 (14%)
History of Ablation	15 (10%)	4 (9%)	0 (0%)
Duration of Atrial Fibrillation			
Unknown	72 (47%)	14 (32%)	3 (43%)
0-1 year	51 (33%)	16 (36%)	2 (29%)
1-5 years	19 (12%)	10 (23%)	2 (29%)

RESULTS FOR 1 YEAR FOLLOW UP

Operative Data for Patients in Sinus Rhythm at 1 Year			
	All Comers (n = 51)	Sinus Rhythm 1 Year Post Op (n = 44)	Abnormal Rhythm 1 Year Post Op (n = 7)
Total Patients in Follow Up Period (n)	51	51	51
Atrial Fibrillation at OR Entry*	12 (24%)	10 (23%)	2 (29%)
Operative Status			
Elective	31 (61%)	27 (61%)	4 (57%)
Urgent	20 (39%)	17 (39%)	3 (43%)
Concomitant Procedure			
CABG	34 (67%)	29 (66%)	5 (71%)
Aortic Procedure	12 (24%)	10 (23%)	2 (29%)
Aortic valve Procedure	15 (29%)	13 (30%)	2 (29%)
Mitral Valve Procedure	4 (8%)	4 (9%)	0 (0%)
Tricuspid Valve Procedure	1 (2%)	1 (2%)	0 (0%)
Cardiopulmonary Bypass Used	50 (98%)	44 (100%)	6 (86%)
Left Atrial Appendage Occlusion			
Epicardial occlusion device	49 (96%)	42 (95%)	7 (100%)
Endocardial Suture	1 (2%)	1 (2%)	0 (0%)
None / Other	1 (2%)	1 (2%)	0 (0%)
Sinus Rhythm at End of Case**	21 (41%)	20 (45%)	1 (14%)

Discharge Information for Patients With 1 Year Follow Up			
	All Comers (n = 51)	Sinus Rhythm 1 Year Post Op (n = 44)	Abnormal Rhythm 1 Year Post Op (n = 7)
Length of Stay	9.7 ± 9.2	8.5 ± 9.9	10.3 ± 5.1
Discharge Location*			
Home	43 (84%)	39 (89%)*	4 (57%)*
Rehab	8 (16%)	5 (11%)*	3 (43%)*
Discharge Anticoagulation			
NOAC	31 (61%)	27 (61%)	4 (57%)
Warfarin	2 (4%)	2 (5%)	0 (0%)
Other Anticoagulant	1 (2%)	1 (2%)	0 (0%)
Discharge Antiarrhythmic			
Amiodarone	26 (51%)	24 (55%)	2 (29%)
Beta Blocker	42 (82%)	35 (80%)	7 (100%)

DISCLOSURES

A Luckert: Intuitive Surgical Solutions (Consultant)



DR Brinster: Cook Medical (Consultant), Terumo Aortic (Consultant), Artivion (Consultant)

NC Patel: Intuitive Surgical Solutions (Consultant)

REFERENCES

Shirasaka T, Kunioka S, Narita M, Ushioda R, Shibagaki K, Kikuchi Y, Wakabayashi N, Ishikawa N, Kamiya H. Feasibility of the AtriClip Pro Left Atrium Appendage Elimination Device via the Transverse Sinus in Minimally Invasive Mitral Valve Surgery. J Chest Surg. 2021 Oct 5;54(5):383-388. doi: 10.5090/jcs.21.048. PMID: 34611086; PMCID: PMC8548185.
Wang E, Sadleir P, Sourinathan V, Weerasooriya R, Playford D, Joshi P. Thoracoscopic Left Atrial Appendage Occlusion with the AtriClip PRO2: An Experience of 144 Patients. Heart Lung Circ. 2024 Aug;33(8):1215-1220. doi: 10.1016/j.hlc.2024.02.010. Epub 2024 Apr 10. PMID: 38604885.

RESULTS FOR 1 YEAR FOLLOW UP



DISCUSSION

- For those patients undergoing closed heart cardiac surgery, concomitant ablation using the AtriCure Encompass device has demonstrated promising rates of maintenance of sinus rhythm at one year follow up.
- Inclusion of the limited box lesion radiofrequency ablation adds operative time, no additional cross clamp time, minimal additional morbidity to the operation and can be performed in an off-pump setting
- Our findings require further exploration as they are from a single institution and offer only a snapshot of rhythm data at follow up assessment with the majority of patients not having outpatient prolonged cardiac monitoring.

CONTACT INFORMATION

JS Newman: jnewman5@northwell.edu.